Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090324
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2004-08-25
Brief Title:
Quetiapine Fumarate SEROQUEL Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-week Multicenter Randomized Double-blind Parallel-group Placebo-controlled Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate SEROQUEL Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia Abbreviated
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANCHOR 112
Brief Summary:
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate SEROQUEL compared with placebo in the treatment of adolescent patients with schizophrenia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None